A randomized, double-blind, phase III, non-inferiority clinical trial comparing the efficacy and safety of TA4415V (a proposed Trastuzumab biosimilar) and Herceptin (Trastuzumab reference product) in HER2-positive early-stage breast Cancer patients
Abstract Background This study compared efficacy and safety of TA4415V, a trastuzumab biosimilar, with reference trastuzumab in patients with human epidermal growth factor receptor 2-positive (HER2-positive) early-stage breast cancer treated in the neoadjuvant setting in Iran. Methods Patients were...
Saved in:
Main Authors: | Reza Safaei Nodehi (Author), Behjat Kalantari (Author), Jahangir Raafat (Author), Nafiseh Ansarinejad (Author), Vahid Moazed (Author), Seyed Mohammad Reza Mortazavizadeh (Author), Mehran Hosseinzadeh (Author), Bayazid Ghaderi (Author), Arash Jenabian (Author), Mojtaba Qadyani (Author), Shirin Haghighat (Author), Abolghasem Allahyari (Author), Mehrzad Mirzania (Author), Mohammad Seghatoleslami (Author), Mehrdad Payandeh (Author), Afsaneh Alikhasi (Author), Hamidreza Kafi (Author), Farhad Shahi (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2022-07-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Validation of ELISA Test-system for Trastuzumab (Herceptin, Hertikad) quantitative determination in biological fluids
by: V. V. Pisarev, et al.
Published: (2023) -
Prática de clínica dos enfermeiros portugueses: administração subcutânea de trastuzumab (herceptin®) e rituximab (mabthera®)
by: Alice Monteiro, et al.
Published: (2018) -
TROIKA‐1: A double‐blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU‐Herceptin® and US‐Herceptin® in healthy male subjects
by: Martin Demarchi, et al.
Published: (2021) -
Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
by: Jiangping Yang, et al.
Published: (2022) -
An unexpected and severe infusion reaction induced by trastuzumab
by: M.ª Sacramento Díaz-Carrasco, et al.
Published: (2014)